Biomea Fusion (Biomea Fusion) 3-Year FCF Growth Rate : -90.90% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion 3-Year FCF Growth Rate?

Biomea Fusion's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.64.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -90.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 5 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Biomea Fusion was -90.90% per year. The lowest was -163.10% per year. And the median was -127.00% per year.

Competitive Comparison of Biomea Fusion's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Biomea Fusion's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's 3-Year FCF Growth Rate falls into.

Biomea Fusion 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Biomea Fusion (NAS:BMEA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Biomea Fusion 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomea Fusion (Biomea Fusion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063

Website

https://www.biomeafusion.com

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Executives

Juan Pablo Frias	officer: Chief Medical Officer	900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc.	10 percent owner	59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director, 10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m.	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle	officer: Chief Financial Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust	director	C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann	director, 10 percent owner, officer: President and COO	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler	director, 10 percent owner, officer: CEO	726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc	10 percent owner	726 MAIN STREET, REDWOOD CITY CA 94063